Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Despite advances in neurosurgical techniques and radio-/chemotherapy, the treatment of
brain tumors remains a challenge. This is particularly true for the most frequent and fatal …

Osteosarcoma is the most common malignant bone tumor in children and adolescence.
Multiple immune-related genes have been reported in different cancers. The aim is to …

Temozolomide (TMZ), an alkylating agent, is widely used for treating primary and recurrent
high-grade gliomas. However, the efficacy of TMZ is often limited by the development of …

SNAREs are the core machinery mediating membrane fusion. In this review, we provide an
update on the recent progress on SNAREs regulating membrane fusion events, especially …

Glioma is one of the most common and lethal brain tumors. Surgical resection followed by
radiotherapy plus chemotherapy is the current standard of care for patients with glioma. The …

Purpose Glioma is the most common primary tumor in the brain, accounting for 81% of
intracranial malignancies. Nowadays, cancer immunotherapy has become a novel and …

Background The regulatory roles of long non-coding RNA (lncRNA) CRNDE in
temozolomide (TMZ) chemoresistance to glioblastoma multiforme (GBM) are still poorly …

Lysosome–autophagosome fusion is critical to autophagosome maturation. Although
several proteins that regulate this fusion process have been identified, the prefusion …

Histone deacetylases are considered to be among the most promising targets in drug
development for cancer therapy. Histone deacetylase 6 (HDAC6) is a unique cytoplasmic …